Kurns - Anything In It For Us?

by Dechert LLP
Contact

A couple of weeks ago – yeah, that’s right, on February 29 – the Supreme Court issued a ruling preempting asbestos product liability claims in Kurns v. Railroad Friction Products Corp., 2012 WL 631857, slip op. (U.S. Feb. 29, 2012).  We’re only now getting around to posting about it because, frankly, there’s not a whole lot in it of interest to us.

The defendants won – the Court found the claims preempted – by 6-3, so that’s good.  But the result was in large part driven by the plaintiffs’ tactical choice (in retrospect unfortunate for them, although maybe the issue was waived below) not to challenge the validity of Napier v. Atlantic Coast Line Railroad Co., 272 U.S. 605 (1926) . Napier had held that the Locomotive Inspection Act (the relevant statute) imposed field preemption, wiping out all state authority, including tort claims, over, among other things, locomotive parts.  That’s because Congress provided that the statute applied to “the entire locomotive and tender and all parts and appurtenances thereof.”  Kurns, 2012 WL 631857, at *4.

T’ain’t no field preemption in prescription medical product liability litigation.  That more than anything else is why we didn’t blog about Kurns before now.  So is there anything there we can use?

A little.

First, even though the supposed presumption against preemption first got its start in field preemption cases (see our post here, citing Rice v. Santa Fe Elevator Corp., 331 U.S. 230 (1947), Jones v. Rath Packing Co., 430 U.S. 519, 525 (1977), and Hillsborough County v. Automated Medical Laboratories, Inc., 471 U.S. 707, 715-18 (1985)), there’s not a peep about the elusive presumption in Kurns.  That’s not really surprising, since Justice Thomas, who eviscerated the presumption against preemption in PLIVA, Inc. v. Mensing, 131 S. Ct. 2567 (2011), is also the author of Kurns.  So we can say, “one more nail in the coffin….”

Another thing we like about Kurns is that it describes preemption in the absence of a statutory preemption clause as “occur[ing] through the direct operation of the Supremacy Clause.”  Id. at *4 (citation and quotation marks omitted).  That’s another beef we have with the presumption against preemption – there’s no principled basis for interpreting the constitution itself as narrowly as flaky decisions like Wyeth v. Levine, 555 U.S. 555 (2009), have done.  Can you imagine a similar presumption against application of the Due Process clause?  The Equal Protection clause?  The First Amendment?  We can’t either.

We also enjoyed the Court’s rare venture into substantive tort law.  Kurns arose in Pennsylvania.  2012 WL 631857, at *3.  That the Court chose (2012 WL 631857, at *7) to discuss Pennsylvania tort principles in terms of the Restatement (Third) of Torts Products Liability §2 (1997) resonates with us because whether Pennsylvania law follows the Second (§402A) or Third Restatement in product liability actions is a matter of considerable dispute – as we discussed in our post, here.  Like the Third Circuit before it, the United States Supreme Court has come down on the side of the newer (and in most, but not all, situations better for defendants) Third Restatement.

The Court’s actual discussion of product liability law was rather arcane – are “warning defects” fundamentally different than “design defects”?  Since a “warning” claim necessarily warns about risks arising from a product’s design, the Court held that the “gravamen” of the warning claim was the design of a locomotive part, which fit within Napier field preemption:

"A failure-to-warn claim alleges that the product itself is unlawfully dangerous unless accompanied by sufficient warnings or instructions.  Thus, the “gravamen” of petitioners’ failure-to-warn claims is still that [plaintiff] suffered harmful consequences as a result of his exposure to asbestos contained in locomotive parts and appurtenances.  Because [plaintiffs’] failure-to-warn claims are therefore directed at the equipment of locomotives, they fall within the pre-empted field defined by Napier."

Kurns, 2012 WL 631857, at *7 (various quotations, including to the Third Restatement, omitted).  Although the Court doesn’t phrase it as such, this is a reiteration of the fundamental principle underlying Restatement §402A, comment k – where a product has inherent risks (as do both asbestos and prescription medical products) warnings are necessary to make an unavoidably unsafe design “reasonable.”

Kurns also included a warning-specific variant of the propositions that tort claims regulate conduct and are therefore properly subject to preemption as state-law “requirements.”  The Court stated:

"This duty to warn and the accompanying threat of liability will inevitably influence a manufacturer’s choice whether to use that particular design.  By influencing design decisions in that manner, failure-to-warn liability has a direct and substantial effect on the physical elements of a [product]."

2012 WL 631857, at *7 n.4 (citation and quotation marks omitted).  This proposition isn’t in serious dispute anymore, see id. at *8 (rejecting for the umpteenth time an argument that the common law is diffferent) – unlike when we were starting out – but it’s nevertheless useful to have another Supreme Court case to cite, if needed.

Finally, the discussion, id. at *8, of a railroad’s right to buy (under Napier) federally compliant products being “meaningless” if the state could prevent defendants from selling them also tends to refute plaintiffs’ assertions of liability for “wrongfully marketing” FDA-approved drugs and devices.  Take the Court’s statement in Kurns, “a railroad’s ability to equip its fleet of locomotives in compliance with federal standards is meaningless if manufacturers are not allowed to produce locomotives and locomotive parts that meet those standards,” and substitute drug/device facts.  Then, one has:

"[A] [hospital’s] ability to equip its[self with prescription medical products] in compliance with [FDA] standards is meaningless if manufacturers are not allowed to produce [drugs and medical devices] that meet those standards."

Id. at *8.  So Kurns is another arrow in our quiver, there, as well.

Not terribly great, but definitely better than nothing.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Dechert LLP | Attorney Advertising

Written by:

Dechert LLP
Contact
more
less

Dechert LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.
Feedback? Tell us what you think of the new jdsupra.com!